Combination Regimens with Colistin Sulfate versus Colistin Sulfate Monotherapy in the Treatment of Infections Caused by Carbapenem-Resistant Gram-Negative Bacilli

Carbapenem-resistant organisms (CRO) have become a global concern because of the limited antibiotic treatment options for CRO infections. Colistin sulfate is a type of polymyxin approved for the treatment of CRO in China. To date, studies on polymyxin have mainly focused on in vitro antibacterial activity or pharmacokinetics/pharmacodynamics, and few have evaluated its clinical efficacy. We aimed to compare the clinical efficacy and safety of colistin sulfate monotherapy and its combination with other antimicrobials in the treatment of carbapenem-resistant Gram-negative bacilli (CR-GNB) infections in adults. This retrospective study included adult patients with CR-GNB infections treated with colistin sulfate by intravenous drip between January and June 2020. The patients were divided into two groups, according to the administration of colistin sulfate alone or in combination with other antibiotics. Group-wise demographic data, comorbidities, clinical efficacy, prognosis, and adverse events were analyzed and compared. In total, 26 patients in the colistin sulfate monotherapy group and 54 patients in the combined therapy group were recruited. The clinical efficacy in the combined therapy group (94.4%) was significantly higher than that in the colistin monotherapy group (73.1%) (p = 0.007); however, the 28-day mortality and length of hospital stay were not significantly different between groups. The incidence of adverse events (including elevated aminotransferase, bilirubin, serum creatinine, and decreased platelet) was not significantly different between the groups. Combination therapies with colistin sulfate are recommended for the treatment of CR-GNB infections, over colistin sulfate alone.

[1]  P. Liu,et al.  Population pharmacokinetics and clinical outcomes of polymyxin B in paediatric patients with multidrug-resistant Gram-negative bacterial infections. , 2022, The Journal of antimicrobial chemotherapy.

[2]  Q. Qu,et al.  Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety , 2022, Infection and Drug Resistance.

[3]  K. Kaye,et al.  Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients , 2021, CPT: pharmacometrics & systems pharmacology.

[4]  F. Franceschi,et al.  Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli. , 2021, International journal of antimicrobial agents.

[5]  C. Chao,et al.  Clinical Efficacy and Safety of Cefoperazone-Sulbactam in Treatment of Intra-Abdominal Infections: A Systematic Review and Meta-Analysis. , 2021, Surgical infections.

[6]  Qiong Lu,et al.  A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections , 2021, Frontiers in Medicine.

[7]  Yibo Fei,et al.  Pharmacokinetics of Colistin in Cerebrospinal Fluid after Intraventricular Administration Alone in Intracranial Infections: Pharmacokinetics of Colistin in CSF. , 2021, International journal of antimicrobial agents.

[8]  Evangelos I. Kritsotakis,et al.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems , 2020, Infection.

[9]  Y. Doi,et al.  Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) , 2020, Emerging microbes & infections.

[10]  M. Antonelli,et al.  Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial , 2019, Critical Care.

[11]  Ronald N. Jones,et al.  Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST) , 2019, Antimicrobial Agents and Chemotherapy.

[12]  Y. Doi Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  A. Oliver,et al.  Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections , 2019, Clinical Microbiology Reviews.

[14]  R. Bonomo,et al.  Polymyxins: To Combine or Not to Combine? , 2019, Antibiotics.

[15]  F. Hu,et al.  Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa , 2019, Antimicrobial Agents and Chemotherapy.

[16]  M. Abdelsalam,et al.  Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. , 2018, Journal of global antimicrobial resistance.

[17]  L. Leibovici,et al.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.

[18]  M. Falagas,et al.  Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. , 2017, International journal of antimicrobial agents.

[19]  K. Yu,et al.  Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli: a Chinese consensus statement. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  Brian T. Tsuji,et al.  Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. , 2015, The Lancet. Infectious diseases.

[21]  V. Miriagou,et al.  Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems , 2014, Antimicrobial Agents and Chemotherapy.

[22]  T. Hirama,et al.  Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects , 2011, Current medical research and opinion.

[23]  O. Zusman,et al.  Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis , 2017, The Journal of antimicrobial chemotherapy.

[24]  M. Ferraro Performance standards for antimicrobial susceptibility testing , 2001 .